Abstract:INTRODUCTION: Hepatitis B virus (HBV) infection is a contagious condition posing a major public health risk in various nations including Vietnam. In 2019, the Ministry of Health introduced tenofovir alafenamide (TAF) to treat patients with chronic HBV infection and reduce the long-term toxicity of tenofovir disoproxil fumarate (TDF). This study aimed to assess the effectiveness and safety of these two medications in individuals with HBeAg-positive chronic HBV. METHODS: This retrospective cohort study included data collected from the medical records of patients with chronic HBV who visited the Liver Clinic at University Medical Center HCMC between 2018 and 2020. RESULTS: After two years of treatment, the proportion of HBeAg loss in the TAF group was twice that of the TDF group (22.4% vs. 11.2%), indicating a statistically significant difference in the probability of HBeAg loss (adjusted hazard ratio = 2.22; 95% CI 1.43 to 3.42; p < 0.01). Additionally, there was a statistically significant difference in the rate and ability of antiviral response between patients treated with TAF and TDF (65% vs. 54.5%, respectively; adjusted hazard ratio = 1.34; 95% CI 1.08 to 1.69; p < 0.01). 93.9% of patients achieved the goal of restoring ALT to normal, a higher percentage compared to the 81.2% in the TDF group, and the likelihood of achieving normal ALT levels with TAF was greater compared to those on TDF (adjusted hazard ratio = 1.67; 95% CI 1.38 to 2.01; p < 0.01). Moreover, there was a statistically significant difference in the variation in renal function between the TAF and TDF groups. Serum creatinine levels in the TAF group increased less than those in the TDF group by 0.03 mg/dL every 6 months (95% CI -0.04 to -0.01, p < 0.01), and the eGFR in the TAF group was higher than that in the TDF group every 6 months by 2.78 mL/min/1.73 m 2 (95% CI 0.98 to 4.57, p < 0.01). However, there was no statistically significant difference in the likelihood of HBeAg seroconversion between chronic hepatitis B patients treated with TAF or TDF (adjusted hazard ratio = 1.79; 95% CI 0.91 to 3.53; p = 0.09), nor in the risk of adverse events between the two groups (adjusted odds ratio = 1.34; 95% CI 0.88 to 2.05; p = 0.17). Additionally, although the HBsAg concentration in the TAF group was lower than in the TDF group by an average of 0.05 log10 IU/mL every 6 months (95% CI -0.15 to 0.05), this difference also did not reach statistical significance (p = 0.35). DISCUSSION: TAF has been demonstrated to achieve some therapeutic efficacy goals and reduce nephrotoxicity better than TDF. However, no differences were found in seroconversion or adverse events between the patient groups.

Effects of Tenofovir Combined with Recombinant Human Interferon Α-2B on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.

Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the treatment of chronic hepatitis B infection: a systematic review and meta-analysis

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B.

The Effects of Entecavir and Adefovirdipivoxil on the Chronic Hepatitis B：a Meta-analysis

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate Versus Emtricitabine and Tenofovir Disoproxil Fumarate As Treatments for Patients with Chronic Hepatitis B

The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study

Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis

A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B

Interferon‐alpha Plus Adefovir Combination Therapy Versus Interferon‐alpha Monotherapy for Chronic Hepatitis B Treatment: A Meta‐analysis

Clinical Efficacy and Incidence of Adverse Reactions of Entecavir Combined with Long-Acting Interferon in Treating Hepatitis B

Clinical Efficacy and Safety of Eight Traditional Chinese Medicine Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis in Adults: A Network Meta-Analysis

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

A meta-analysis of comparison of efficacy of tenofovir or entecavir in nucleos(t)ide analogue-naive patients with chronic hepatitis B

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA

Effects of IFN monotherapy versus combined therapy on HBeAg seroconversion or seroclearance in HBeAg-positive chronic hepatitis B patients: A meta-analysis

Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study

Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B

Effect of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cell

Clinical Efficacy And Safety of Long-Term Treatment Of Tenofovir Alafenamide Vs Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam